CTNNB1 and neoplasm: Accordingly, tumours with CTNNB1 mutation showed low PRRX1 level (P < 0.0001), whereas no expression change was observed with TP53 mutations (Fig. 1c), suggesting that the different oncogenic background influences PRRX1 level.